Ad is loading...
CSBR
Price
$4.50
Change
+$0.04 (+0.90%)
Updated
Nov 15 closing price
29 days until earnings call
MYNDF
Price
$0.01
Change
-$0.00 (-0.00%)
Updated
Nov 12 closing price
Ad is loading...

CSBR vs MYNDF

Header iconCSBR vs MYNDF Comparison
Open Charts CSBR vs MYNDFBanner chart's image
Champions Oncology
Price$4.50
Change+$0.04 (+0.90%)
Volume$4.95K
CapitalizationN/A
MYND Life Sciences
Price$0.01
Change-$0.00 (-0.00%)
Volume$300
CapitalizationN/A
CSBR vs MYNDF Comparison Chart
Loading...
View a ticker or compare two or three
VS
CSBR vs. MYNDF commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CSBR is a Sell and MYNDF is a Buy.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (CSBR: $4.50 vs. MYNDF: $0.01)
Brand notoriety: CSBR and MYNDF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CSBR: 7% vs. MYNDF: 144%
Market capitalization -- CSBR: $61.17M vs. MYNDF: $1.7M
CSBR [@Biotechnology] is valued at $61.17M. MYNDF’s [@Biotechnology] market capitalization is $1.7M. The market cap for tickers in the [@Biotechnology] industry ranges from $472.8B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CSBR’s FA Score shows that 0 FA rating(s) are green whileMYNDF’s FA Score has 1 green FA rating(s).

  • CSBR’s FA Score: 0 green, 5 red.
  • MYNDF’s FA Score: 1 green, 4 red.
According to our system of comparison, MYNDF is a better buy in the long-term than CSBR.

Price Growth

CSBR (@Biotechnology) experienced а +0.56% price change this week, while MYNDF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.

Reported Earning Dates

CSBR is expected to report earnings on Mar 18, 2025.

Industries' Descriptions

@Biotechnology (-8.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

FUNDAMENTALS
Fundamentals
CSBR($61.2M) has a higher market cap than MYNDF($1.7M). CSBR YTD gains are higher at: -19.927 vs. MYNDF (-59.936). MYNDF has higher annual earnings (EBITDA): -273.7K vs. CSBR (-6.81M). CSBR has more cash in the bank: 10.1M vs. MYNDF (1.81K). MYNDF has less debt than CSBR: MYNDF (3M) vs CSBR (7.74M). CSBR has higher revenues than MYNDF: CSBR (49.2M) vs MYNDF (1).
CSBRMYNDFCSBR / MYNDF
Capitalization61.2M1.7M3,600%
EBITDA-6.81M-273.7K2,487%
Gain YTD-19.927-59.93633%
P/E RatioN/AN/A-
Revenue49.2M14,920,000,000%
Total Cash10.1M1.81K558,937%
Total Debt7.74M3M258%
FUNDAMENTALS RATINGS
CSBR: Fundamental Ratings
CSBR
OUTLOOK RATING
1..100
7
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
59
P/E GROWTH RATING
1..100
54
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
RSI
ODDS (%)
Stochastic
ODDS (%)
Momentum
ODDS (%)
MACD
ODDS (%)
TrendWeek
ODDS (%)
TrendMonth
ODDS (%)
Advances
ODDS (%)
Declines
ODDS (%)
BollingerBands
ODDS (%)
Aroon
ODDS (%)
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FAPLX13.24-0.13
-0.97%
Fidelity Advisor Healthy Future M
LKEQX40.66-0.49
-1.19%
LKCM Equity
MXKWX9.63-0.13
-1.33%
Empower S&P 500® Index Institutional
MUEUX39.47-0.62
-1.55%
MFS Blended Research Core Equity R4
TMCAX12.90-0.27
-2.05%
RBC SMID Cap Growth A

CSBR and

Correlation & Price change

A.I.dvisor tells us that CSBR and SYRE have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CSBR and SYRE's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CSBR
1D Price
Change %
CSBR100%
+0.90%
SYRE - CSBR
32%
Poorly correlated
-6.62%
SCNI - CSBR
27%
Poorly correlated
-4.36%
OABI - CSBR
25%
Poorly correlated
-4.67%
PLUR - CSBR
24%
Poorly correlated
-1.28%
MNOV - CSBR
24%
Poorly correlated
+0.27%
More

MYNDF and

Correlation & Price change

A.I.dvisor tells us that MYNDF and NERV have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MYNDF and NERV's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MYNDF
1D Price
Change %
MYNDF100%
N/A
NERV - MYNDF
29%
Poorly correlated
-5.17%
ICCC - MYNDF
23%
Poorly correlated
+0.28%
CSBR - MYNDF
20%
Poorly correlated
+0.90%
AEON - MYNDF
7%
Poorly correlated
+0.87%
INKT - MYNDF
4%
Poorly correlated
+0.53%
More